Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2008 1
2018 2
2021 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Your search for Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas retrieved no results
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.
Poggio T, Duyster J, Illert AL. Poggio T, et al. Cancers (Basel). 2018 Sep 18;10(9):339. doi: 10.3390/cancers10090339. Cancers (Basel). 2018. PMID: 30231561 Free PMC article. Review.
T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system. ...Chimeric antigen receptor (CAR)-T cells directed against CD30 and immune checkpoint inhibitors are currently being investigated in clin
T cell non-Hodgkin lymphoma (T-NHL) is a rare and heterogeneous group of neoplasms of the lymphoid system. ...Ch
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, Dermime S. Maalej KM, et al. Mol Cancer. 2023 Jan 30;22(1):20. doi: 10.1186/s12943-023-01723-z. Mol Cancer. 2023. PMID: 36717905 Free PMC article. Review.
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. ...In hematological malignancies like leukemias, myeloma, and non-Hodgkin B-cell lymphomas, …
In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic appr
Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma.
Castaneda-Puglianini O, Chavez JC. Castaneda-Puglianini O, et al. Drugs Context. 2021 Sep 21;10:2021-2-4. doi: 10.7573/dic.2021-2-4. eCollection 2021. Drugs Context. 2021. PMID: 34603459 Free PMC article. Review.
Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antibody-drug conjugates, immune-checkpoint inhibitors and chimeric antigen receptor T cell therapies with important success. Bispe …
Immunotherapy has revolutionized the treatment of cancers. There are several approaches, including naked monoclonal antibodies, antib …
Lymphoma of the skin.
Connors JM, Hsi ED, Foss FM. Connors JM, et al. Hematology Am Soc Hematol Educ Program. 2002:263-82. doi: 10.1182/asheducation-2002.1.263. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446427 Review.
Francine Foss concludes the session with a discussion of the different T-cell lymphomas that start in or spread to the skin concentrating on mycosis fungoides, cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma. She includes …
Francine Foss concludes the session with a discussion of the different T-cell lymphomas that start in or spread to the …
Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber ANR, Cardona Gloria Y, Çınar Ö, Reinhardt HC, Pezzutto A, Wolz OO. Weber ANR, et al. Cancer Immunol Immunother. 2018 Nov;67(11):1797-1807. doi: 10.1007/s00262-018-2242-9. Epub 2018 Sep 11. Cancer Immunol Immunother. 2018. PMID: 30203262 Review.
Oncogenic MYD88 mutations, most notably the Leu 265 Pro (L265P) mutation, were recently identified as potential driver mutations in various B-cell non-Hodgkin Lymphomas (NHLs). The L265P mutation is now thought to be common to virtually all NHLs and occurs in …
Oncogenic MYD88 mutations, most notably the Leu 265 Pro (L265P) mutation, were recently identified as potential driver mutations in various …
Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
Raghani NR, Shah DD, Shah TS, Chorawala MR, Patel RB. Raghani NR, et al. Crit Rev Oncol Hematol. 2023 Oct;190:104085. doi: 10.1016/j.critrevonc.2023.104085. Epub 2023 Aug 2. Crit Rev Oncol Hematol. 2023. PMID: 37536448 Review.
Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin's lymphoma (NHL), accounting for 5% of all cases. Due to its virulence factor, it is an incurable disease and keeps relapsing despite an intensive treatment regimen. ...Brexucabtagene Aut …
Mantle cell lymphoma (MCL) is a rare, aggressive subtype of non-Hodgkin's lymphoma (NHL), accounting for 5% of all cases. Due …
Novel virally targeted therapies of EBV-associated tumors.
De Paoli P. De Paoli P. Curr Cancer Drug Targets. 2008 Nov;8(7):591-6. doi: 10.2174/156800908786241069. Curr Cancer Drug Targets. 2008. PMID: 18991568 Review.
EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitt's Lymphoma, post-transplant lymphoproliferative disorders, Hodgkin's disease, AIDS-associated lymphomas, NK/T cell lymphoma and Nas …
EBV is associated to the development of several malignancies of lymphoid and epithelial origin, including Burkitt's Lymphoma, post-transplan …
SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
Nayak RK, Gerber D, Zhang C, Cohen JB. Nayak RK, et al. Clin Lymphoma Myeloma Leuk. 2023 Dec;23(12):861-865. doi: 10.1016/j.clml.2023.08.011. Epub 2023 Aug 14. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37661513 Review.
Mantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or refractory (R/R) disease for many patients. ...This review article aims to provide a comprehensive overview …
Mantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and …
Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
Gordon MJ, Sureda A, Westin JR. Gordon MJ, et al. Leuk Lymphoma. 2022 Sep;63(9):2041-2051. doi: 10.1080/10428194.2022.2068007. Epub 2022 May 12. Leuk Lymphoma. 2022. PMID: 35549635
In second-line, the standard treatment strategy for fit patients has been high dose chemotherapy followed by autologous stem cell transplant for a quarter-century, however more than half of patients have chemotherapy-refractory disease with this approach. The patien …
In second-line, the standard treatment strategy for fit patients has been high dose chemotherapy followed by autologous stem cell transplant …
An array of immunotherapeutic strategies for B-cell lymphomas.
Schultze JL. Schultze JL. Expert Opin Investig Drugs. 1999 Dec;8(12):2059-2071. doi: 10.1517/13543784.8.12.2059. Expert Opin Investig Drugs. 1999. PMID: 11139840
With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non-Hodgkin's-lymphomas (NHL) has gained momentum. Since the first description of the CD20 mAb and its use in a single patient, it …
With FDA approval of monoclonal antibodies (mAb) against the B-cell-specific cell surface molecule CD20, immunotherapy in B-cell non- …